Examination of sTWEAK in type 2 diabetic patients with nephropathy and its clinical significances
CHAO Bei1, SHI Wei-Feng2, ZHANG Li-rong2, ZHANG Zhi-jian1
(1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of Clinical Laboratory, the First People′s Hospital of Changzhou, Changzhou Jiangsu 213003, China)
Abstract：Objective: To explore the clinical significances of the serum TNF like weak inducer of apoptosis (sTWEAK) in the diagnosis of diabetic nephropathy and the evaluation of the therapeutic efficacy of the disease. Methods: The objects were divided into 40 cases of healthy control group (group NC); 60 cases of simple type 2 diabetes mellitus group(group T2DM); and 103 cases of type 2 diabetic patients with nephropathy group(group T2DN). According to the Mogensen classification of kidney damage degree, the T2DN group was further divided into three subgroups: normal albuminuria group(NAU),microalbuminuria group(MAU) and macroalbuminuria group(MaAU).The concentrations of sTWEAK in the serum of three groups were examined by ELISA method.In addition, the concentrations of sTWEAK in T2DN patients,before and after treatment, were compared. Results: Different levels of the sTWEAK in the three groups could be detected. In T2DN group and T2DM group, the contents of sTWEAK were significantly lower than that in NC group(P＜0.01);in T2DN group, the content of sTWEAK was significantly lower than that in T2DM group(P＜0.01). Along with the increase of the degree of renal damage,the concentration of sTWEAK decreased(P＜0.01);after treatment, the concentration of sTWEAK increased obviously(P<0.05). Conclusion: Examination of sTWEAK in type 2 diabetic patients with nephropathy had the clinical significances in the diagnosis and the evaluation of the therapeutic efficacy of the disease.
收稿日期: 2014-05-08
通讯作者:
张志坚（通讯作者），副研究员，硕士生导师，E-mail:zzj@ujs.edu.cn
作者简介: 巢蓓（1981—），女，江苏常州人，主管技师，主要从事临床医学检验工作；
引用本文:
巢蓓， 史伟峰， 张丽荣， 张志坚. 2型糖尿病肾病患者血清sTWEAK蛋白含量的测定及其临床意义[J]. 江苏大学学报:医学版, 2014, 24(04): 320-323.
CHAO Bei1, SHI Wei-Feng2, ZHANG Li-rong2, ZHANG Zhi-jian1. Examination of sTWEAK in type 2 diabetic patients with nephropathy and its clinical significances. Journal of Jiangsu University(Medicine Edition), 2014, 24(04): 320-323.
[1]李敏州，高彦彬,马鸣飞,等.糖尿病肾病发病机制研究进展\[J\].中国实验方剂学杂志，2012，18(22)：165-169.［2］Chorianopoulos E,Jarr K,Steen H,et al.Soluble TWEAK is markedly upregulated in patients with STelevation myocardial infarction and relatde to an adverse shortterm outcome\[J\].Atherosclerosis，2010,211(1):322-326.［3］Jasiewicz M, Kowal K, KowalBielecka O, et al. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension\[J\].Cytokine,2014,66(1):40-45.［4］夏志银，马玉华,董海英,等.促红素促进慢性肾功能不全患者STWEAK蛋白表达\[J\].四川医学，2013，34（12）:1877-1880.［5］高智亭,潘海洋, 刘殿昌,等. 肿瘤坏死因子样凋亡微弱诱导剂在原发性肝癌患者血清中的表达及其意义\[J\].中国现代普通外科进展，2013,16（2）：112-116.［6］王其磊,任满意,王德金,等.TWEAK通过P38MAPK途径促进大鼠心肌成纤维细胞Ⅰ型胶原和MMP-1的表达\[J\].山东大学学报:医学版，2012,50(11):134-136.［7］Yilmaz MI, Carrero JJ, Ortiz A,et al. Soluble TWEAK plasma levels as a novek biomarker of endothelial function in patients with chronic kideney disease\[J\].Clin J Am Soc Nephrol, 2009,4(11):1716-1723.［8］Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting\[J\].Nat Rev Drug Discov,2008,7(5):411-425.［9］Bover LC, Cardo-Vila M,Kuniyasu A, et al. A previously unrecognized proteinprotein interaction between TWEAK and CD163:potential biological implications\[J\].J Immunol,2007,178(12):8183-8194.［10］张文文.腹膜透析患者血清TWEAK水平与微炎症状态及动脉粥样硬化的相关性研究\[D\].苏州：苏州大学，2012.
2014, Vol. 24 
